Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of t...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2020-07-01
|
| シリーズ: | Journal of Cardiovascular Development and Disease |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2308-3425/7/3/25 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|